证券代码：600079 证券简称：人福医药 编号：临 2025-095 人福医药集团股份公司 第十一届董事会第一次会议决议公告 特 别 提 示 人福医药集团股份公司（以下简称"公司"或"人福医药"）第十一届董事会第一 次会议于2025年7月31日（星期四）以现场结合通讯表决方式召开，会议通知已于2025 年7月30日以电话、口头等方式发出，经全体董事一致同意豁免本次会议通知时限要求。 会议应到董事九名，实到董事九名，其中独立董事田卫星女士以通讯方式参加。公司高 级管理人员列席了会议。根据人福医药《公司章程》和《董事会议事规则》等相关规定， 全体董事共同推举邓伟栋先生主持本次会议。本次会议的召集、召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定，所做决议合法有效。 二、董事会会议审议情况 （一）审议通过《关于选举公司第十一届董事会董事长的议案》 同意选举邓伟栋先生为公司第十一届董事会董事长，任期三年，自本次董事会审议 通过之日起至第十一届董事会任期届满之日止。 表决结果：同意9票、反对0票、弃权0票。具体内容详见公司同日在上海证券交易 所网站（www.sse.com.cn）披露的《关于董事 ...

Group 1 - The core point of the article is that Renfu Pharmaceutical has received approval from the National Medical Products Administration for the drug registration certificate of Drospirenone and Ethinyl Estradiol Tablets [2] - In the fiscal year 2024, Renfu Pharmaceutical's revenue composition is as follows: pharmaceuticals account for 56.01%, pharmaceutical wholesale and related businesses account for 43.8%, and other businesses account for 0.19% [2]

Core Viewpoint - The approval of the drug "Drospirenone and Ethinyl Estradiol Tablets" by the National Medical Products Administration marks a significant milestone for the company, allowing it to sell this product in the domestic market, which will positively impact its product line and overall business performance [1]. Group 1 - The company’s subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., has received the drug registration certificate for Drospirenone and Ethinyl Estradiol Tablets [1]. - The approval indicates that the company is now qualified to market this drug in China, enhancing its product offerings [1]. - The company plans to arrange for the production and market launch of the drug based on market demand [1].

Core Viewpoint - The company, Renfu Pharmaceutical, has received approval from the National Medical Products Administration for the registration of a contraceptive drug, Drospirenone and Ethinyl Estradiol Tablets [1] Company Summary - Renfu Pharmaceutical's subsidiary, Jiulong Renfu, has been granted a drug registration certificate for Drospirenone and Ethinyl Estradiol Tablets, which are intended for female contraception [1]

Core Viewpoint - The company, Renfu Pharmaceutical, announced that its subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., has received the drug registration certificate for Drospirenone and Ethinyl Estradiol Tablets from the National Medical Products Administration, indicating a new product launch in the contraceptive market [1]. Group 1 - Renfu Pharmaceutical's subsidiary, Jiulong Renfu, holds 100% ownership by another subsidiary, Hubei Gedian Renfu Pharmaceutical Co., Ltd. [1] - The newly approved drug, Drospirenone and Ethinyl Estradiol Tablets, is intended for female contraception [1].

格隆汇7月31日丨人福医药（维权）(600079.SH)公布，公司于2025年7月30日召开2025年第三次临时股 东会，审议通过董事会换届选举相关议案。截至目前，公司第一大股东招商生命科技（武汉）有限公司 （简称"招商生科"）已完成对公司董事会改组等程序并已对公司形成控制，公司控股股东变更为招商生 科，实际控制人变更为招商局集团有限公司。 ...

Core Viewpoint - The approval of the drug "Drosperinone and Ethinyl Estradiol Tablets" by the National Medical Products Administration marks a significant milestone for the company, enabling it to sell the product in the domestic market and enhancing its product line [1] Group 1 - The company's subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., received the drug registration certificate for Drosperinone and Ethinyl Estradiol Tablets [1] - The drug is intended for female contraception and the company submitted its application for marketing authorization in March 2024, which has been accepted [1] - The total R&D investment for this product amounts to approximately RMB 8.5 million [1] Group 2 - The projected national sales revenue for Drosperinone and Ethinyl Estradiol Tablets in 2024 is approximately RMB 320 million [1] - The approval signifies the company's qualification to market the drug domestically, which is expected to have a positive impact on its business [1]

人福医药（600079）公告，公司于2025年7月30日召开2025年第三次临时股东会，审议通过董事会换届 选举相关议案。截至目前，公司第一大股东招商生命科技(武汉)有限公司已完成对公司董事会改组等程 序并已对公司形成控制，公司控股股东变更为招商生科，实际控制人变更为招商局集团有限公司。2025 年6月26日，当代科技所持人福医药3.87亿股已通过司法划转方式办理完成股份过户登记手续。通过本 次股份过户，招商生科直接持有、通过其控制的有限合伙企业间接持有和接受信托计划表决权委托方式 合计控制公司3.87亿股普通股表决权，占公司总股本的23.70%。 ...

Group 1 - The core point of the article is that the company, Renfu Pharmaceutical, has received a drug registration certificate for its contraceptive product, Cyproterone Acetate and Ethinylestradiol Tablets, from the National Medical Products Administration [1] - The product is intended for female contraception and will be managed as a Class A over-the-counter drug after approval [1] - The company invested approximately 8.5 million yuan in the research and development of this product, which was submitted for approval in March 2024 [1] Group 2 - The estimated national sales for Cyproterone Acetate and Ethinylestradiol Tablets in 2024 is around 320 million yuan [1] - The approval signifies that the company is now qualified to sell this product in the domestic market, thereby enriching its product line [1] - Future sales performance may be influenced by industry policies and market conditions [1]

湖北山河律师事务所 Hubei S&H Law Firm 人福医药集团股份公司 法律意见书 （2025）山河非章第 3018 号 致：人福医药集团股份公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东 会规则》（以下简称"《股东会规则》"）以及《人福医药集团股份公 司章程》（以下简称"《公司章程》"）《人福医药集团股份公司股东 大会议事规则》（以下简称"《股东大会议事规则》"）等内部规章制 度的有关规定，湖北山河律师事务所（以下简称"本所"）接受人福医 药集团股份公司（以下简称"人福医药"或"公司"）的委托，指派本 所执业律师（以下简称"本所律师"）出席人福医药 2025 年第三次临 时股东会（以下简称"本次股东会"）并出具法律意见。 为出具本法律意见书，本所律师出席了本次股东会，审查了公司提 供的有关本次股东会的相关文件，听取了公司董事会就有关事项所作的 说明。本所已得到人福医药的如下保证：人福医药已向本所提供了出具 法律意见书所必需的、真实的原始书面材料、副本材料或口头证言。其 所提供的书面材料、副本材料或口头证言均是真实、准 ...